åêðáéäåõóçó γ.ν.α.

506 Δείκτες κυτταρικού πολλαπλασιασμού, απόπτωσης: Κινάση Θυμιδίνης, Κυτταροκερατίνες
Kδllander CFR: Thymidine kinase: Biochemical backround
and clinical applications. I. Backround and use
in gene therapy. II. The quantitative assay for TK and
its clinical use. III. Use of TK assay in serum, plasma
and other body fluids. εύρεση στο δικτυακό τόπο:
http://www.biovica.com/thymidine1.htm
42. öhrvik A, Lindh M, Einarsson R et al: Sensitive nonradiometric
method for determining Thymidine Kinase 1
activity. Clin Chem 2004; 50(9): 1597-1606.
43. Ellims PH, Gan ET, Medley G et al: Prognostic relevance
of Thymidine Kinase Isozymes in adult Non-Hodgkin’s
lymphoma.Blood 1981; 58(5): 926-30.
44. Seiler T, Döhner H, Stilgenbauer S: Risk stratification
in chronic lymphocytic leukemia. Semin Oncol 2006;
33(2):186-194.
45. Gronowitz JS, Seinholtz L, Clas F et al: Serum deoythymidine
kinase in small cell carcinoma of the lung: Relation
to clinical features, prognosis and other biochemical
markers Cancer 1986; 58:111-18.
46. Li HX, Lei DS, Wang XQ et al: Serum thymidine kinase
1 is a prognostic and monitoring factor in patients with
non-small cell lung cancer. Oncol Rep 2005; 13(1):
145-9.
47. Letocha H, Eklöv S, Gronowitz S et al: Deoxythymidine
kinase in the staging of prostatic adenocarcinoma.
Prostate 1996; 29: 15-19.
48. He Q, Fornander T, Johansson H et al: Thymidine
kinase 1 in serum predicts increased risk of distant or
locoregional recurrence following surgery in patients
with early breast cancer. Anticancer Res 2006; 26(6C):
4753-9.
49. Foekens JA, Romain S, Look MP et al: Thymidine Kinase
and Thymidylate Synthase in advanced breast cancer:
response to tamoxifen and chemotherapy Cancer Res
2001; 61:1421-25.
50. Zhang J, Jia Q, Zou S et al: Thymidine kinase 1: a proliferation
marker for determining prognosis and monitoring
the surgical outcome of primary bladder cancer. Oncol
Rep 2006; 15(2): 455-61.
xxxxxxxxxxx
xxxxxx